Ranibizumab, a humanized anti-VEGF-A Ab fragment, and brolucizumab, a single-chain anti-VEGF-A Ab, continue to improve retinal disease outcomes.661,662 The NORSE-EIGHT clinical trial validated ranibizumab’s superior efficacy over bevacizumab in improving best-corrected visual acuity.663 Notably, bevacizumab, under the brand name LYTENAVATM, has received regulatory approval for wet AMD treatment in the EU and UK.664. Here, VEGFA is linked to wet macular degeneration.